# Immune Tolerance Network-NIDDK 2024 Supplement

> **NIH NIH UM1** · BENAROYA RESEARCH INST AT VIRGINIA MASON · 2024 · $2,642,000

## Abstract

Project Summary / ABSTRACT
The mission of the ITN is to advance the clinical application of immune tolerance by performing
high quality clinical trials of emerging therapeutics based upon testable mechanistic hypotheses.
The ITN is structured in order to interrogate different diseases across the immunologic
spectrum, with integration of innovative clinical studies and cutting edge immunology laboratory
analysis. The ITN approach—clinical assessment of novel tolerance therapeutics, while we
simultaneously evaluate the cellular, genetic, and immunologic mechanisms of disease and how
they are altered in response to therapy—creates a framework for advancing cross-disease and
cross-discipline knowledge, all designed to accelerate therapeutic options for major diseases.
Since its inception, one of the areas of interest of the ITN has been Type 1 Diabetes (T1D) with
a focus to successfully enhance the development of tolerance therapies. We outline a process
to evolve our current strategies into the next generation of planned trials, as well as how we
plan to operate a nimble, future-focused organization, poised to lead and adopt innovations that
are currently unknown. We utilize a collaborative structure involving hundreds of investigators,
advisors, and clinical sites and mechanistic laboratories working in tandem with a core group of
ITN staff, operating a program that is both scientifically and financially efficient. With lead
institutional commitment from the Benaroya Research Institute and the University of California
San Francisco, and participation of more than 20 other major institutions represented in
leadership and major advisory roles, the ITN strives to continue to successfully pioneer high
impact clinical trials and mechanistic studies in T1D.

## Key facts

- **NIH application ID:** 11121475
- **Project number:** 3UM1AI109565-11S2
- **Recipient organization:** BENAROYA RESEARCH INST AT VIRGINIA MASON
- **Principal Investigator:** Mark S Anderson
- **Activity code:** UM1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $2,642,000
- **Award type:** 3
- **Project period:** 2014-02-01 → 2028-01-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11121475

## Citation

> US National Institutes of Health, RePORTER application 11121475, Immune Tolerance Network-NIDDK 2024 Supplement (3UM1AI109565-11S2). Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/grant/nih/11121475. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*